dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Jul 30, 2015 12:25:25 GMT -5
Headlines
8:33 am Novavax announces positive top-line data from its Phase 2 clinical trial of the company's recombinant quadrivalent seasonal flu VLP candidateBriefing.com(Thu 8:33AM EDT)
Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLPGlobeNewswire(Thu 8:30AM EDT)
Day's Range: 11.76 - 12.25
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Aug 11, 2015 19:17:16 GMT -5
Novavax Inc. (NVAX - Snapshot Report) is a specialty biopharmaceutical company that focuses on the research and development of vaccines and anti-viral treatments. Based in Maryland, Novavax is a “clinical stage” company, meaning that it is on the cutting edge of discovering and testing new medicines.
Novavax made the news today after announcing the success of mid-stage trials for a vaccine to prevent the respiratory syncytial virus (PSV). The vaccine lowered the risk of getting PSV by 46% versus the placebo when given to elderly patients. PSV is attributed to about 14,000 deaths annually.
Currently, NVAX is up over 20% from yesterday’s close, as investors are clearly excited about the potential of this groundbreaking vaccine. If you aren’t very familiar Novavax and are now considering it for your portfolio, we’ve highlighted five key facts about the company to help you as you consider an investment.
1. On the brink of history
Novavax’s new PSV drug has the potential to be historically important for several reasons. From a medicinal perspective, it could be the culmination of over 60 years of research that many scientists did not think would ever come to fruition. This drug could save thousands of lives and become a staple vaccination for older people.
From a business perspective, this new vaccine could be a record-breaking revenue stream. The company hopes to target all adults over 60 years old. That’s over 55 million potential customers in the United States alone. Novavax CEO Stan Erck said, “I believe it will exceed the world’s largest-selling vaccine.”
2. Coming off a great day
The news about the PSV drug’s trial was announced Monday afternoon, but that wasn’t the only good news that day. Monday also marked the release of Novavax’s latest earnings report, and the numbers looked positive. For one, the company posted an EPS that beat the Zacks Consensus Estimate by 11.11%. Also, Novavax crushed our revenue estimate of $10 million, reporting $14 in revenues for the quarter.
3. Older than you might think
As mentioned before, the new PSV drug is the continuation of decades of research. Novavax has also been around for quite a long time, and despite this new popularity, the company has been running steady since its founding in 1987. In that time, Novavax has conducted 14 clinical trials, 11 of which are completed. This isn’t a young volatile company, but one with a rich history of research and discovery.
4. Experienced leaders
It’s always important for a groundbreaking company like this to be led by the right people. With Novavax, there seems to be a solid mix of business and pharmaceutical experience. For example, James F. Young, the Chairman of the Board of Directors, was formally the President of Research and Development at MedImmune, where he helped develop FluMist and Synagis. Novavax’s CEO Stan Erck was previously at the IAOMI Corporation, where he helped the company through an initial public offering and a major acquisition.
5. Top workplace
For the second year in a row, Novavax was named one of the Washington Post’s Top Workplaces. These rankings are entirely based on employee feedback, meaning that Novavax’s employees are happy and comfortable in their workplace. Good morale from the workforce is generally a sign of good management, and definitely helps production and motivation.
Bottom Line
The news about Novavax’s clinical trial helped its stock price skyrocket, and a vaccine that monumental is sure to keep the company in the spotlight until the final results are in. Simply put, Novavax is a stock to watch right now. Currently, Novavax has a Zacks Rank #3 (Hold), but it will be interesting to see if the recent news spurs any earnings estimate revision activity. Regardless, investors need to get to know this company now.
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Aug 19, 2015 10:16:55 GMT -5
Stars Align for Novavax
Published: 4 hours ago Speaker Image
By: John McCamant
In the large Phase II trial, Novavax (NVAX) has delivered excellent respiratory syncytial virus (RSV) protein vaccine data in the most difficult-to-treat elderly population (over 60 years old).
The study is the first ever demonstration of efficacy of an active RSV vaccine in humans and resulted in statistically significant efficacy in prevention of all symptomatic RSV disease (44%) and RSV disease with symptoms of lower respiratory tract infection (46%) in older adults.
Importantly, no serious vaccine related side effects were reported. The vaccine was well tolerated and met all primary, secondary, and exploratory objectives of the trial.
The observed efficacy was similar to or better than multiple recent effectiveness estimates for a number of respiratory vaccines that are currently approved in older adults, including pneumococcal and standard-dose seasonal influenza.
These data give NVAX enormous confidence and information, as they will meet with the FDA next to agree on a Phase III trial design, estimated to include 8,000-10,000 people.
With the positive Phase II data in the elderly now delivered, in our view, the stars have aligned for NVAX and they should be able to start Phase III by yearend and test in the Northern hemisphere this winter. ........ CONTINUED - www.moneyshow.com/articles.asp?aid=tptp072513-43224
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Sept 2, 2015 16:23:02 GMT -5
SCHEDULE ATTACHED: Multiple Investor Conferences in September
NOVAVAX, a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the Company will participate in the FBR 2(nd) Annual Healthcare Conference and the Citi 10(th) Annual Biotech Conference.
Conference details are as follows:
FBR 2(nd) Annual Healthcare Conference
Date: Wednesday, September 9, 2015
Forum: One-on-one meetings
Location: Four Seasons Hotel, Boston
Citi 10(th) Annual Biotech Conference
Date: Thursday, September 10, 2015
Forum: Panel discussion, Preventing and Treating Viral Infections: Vaccines and Antivirals
Time: 8:00 -- 8:55 a.m. US Eastern Time
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Sept 2, 2015 16:37:12 GMT -5
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
NOVAVAX
Oct 27, 2015 14:00:40 GMT -5
Post by dothedd on Oct 27, 2015 14:00:40 GMT -5
October 27, 2015
Novavax (NVAX - Snapshot Report) saw its stock move higher as Ebola scares gripped the nation. Since then, concerns of drug prices being too high has hurt the entire industry and maybe disproportionately hurt shares of NVAX. Analysts have actually become more bullish on the stock and have raised The increases in earnings estimates have helped push the stock to a Zacks Rank #1 (Strong Buy) and today it is the Bull of the Day. - See more at: www.zacks.com/commentary/60424/bull-of-the-day-novavax-nvax#sthash.pkRbWslG.dpuf
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
NOVAVAX
Oct 27, 2015 14:03:03 GMT -5
Post by dothedd on Oct 27, 2015 14:03:03 GMT -5
CLINICAL STAGE PIPELINE
Novavax’s clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection. Our recombinant nanoparticles and Matrix™ adjuvant technology are the foundation for groundbreaking innovation that holds the promise of improving immune responses and protection from traditional seasonal infectious disease and the threat of infectious pathogens with pandemic potential.
novavax.com/page/11/clinical-stage-pipeline
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
NOVAVAX
Oct 27, 2015 14:05:43 GMT -5
Post by dothedd on Oct 27, 2015 14:05:43 GMT -5
Scientific Presentations FIGO World Congress of Gynecology and Obstetrics
RSV F Vaccine: Phase 2 Clinical Trial to Protect Infants via Maternal Immunization
WHO 5th Teleconference on Ebola Vaccine Clinical Trials
Novavax Ebola/Makona Glycoprotein (GP) Nanoparticle Vaccine Candidate Update: NHP and Clinical Data
WHO Briefing
Recombinant Nanoparticle Vaccine Using Ebola Guinea 2014 GP Sequence
Atlantic Vaccines Summit & Immunotherapeutics Summit
Rapid Responses to Novel Lethal Viruses
World Vaccine Congress
RSV F Nanoparticle Vaccine
Rapid Responses to Novel Lethal Viruses
7th International Symposium on Filoviruses
Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells
2015 ISBioTech Meeting
EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells
Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology
novavax.com/page/13/presentations
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
NOVAVAX
Oct 27, 2015 14:16:24 GMT -5
Post by dothedd on Oct 27, 2015 14:16:24 GMT -5
|
|
